Skip Navigation
About FRD
    For Inventorsfor IndustryFor Entrprenuers
Online Licensing
Available Technologies

Information and Resources


Frequently Asked Questions

 Start-Up Resources 
 SBIR/STTR Programs 
  • Targeting CD26hi T-cells for Cancer Therapy
    Inventors at MUSC have identified a unique human CD4+ T cell population that expresses high levels of surface CD26, termed CD26high T cells, which mediate durable antitumor immunity in vivo, and have immediate clinical relevance for designing new vaccines and cellular therapies.

     CD26high T cells simultaneously secrete elevated IL-17A, IFN-? and IL-22 compared to Th1, Th2 or Th17 cells. When infused into mice bearing human tumors, CD26high T cells more efficiently reconstituted immunodeficient hosts and persisted long-term compared to other subsets. Remarkably, CD26high T cells engineered with a first generation CD3? mesothelin-specific chimeric antigen receptor (CAR) were capable of ablating large human mesothelioma tumors when infused into mice. 


  • Spinal Implant System for Reduction & Internal Implant Stabilization of Human Spondylolisthesis Deformity
    The Hercules spinal implant device and system is to be used for reduction and internal implant stabilization of human vertebral spondylolisthesis deformity. It is a standalone system with unique design that allows an anterior surgical approach to realign and simultaneously stabilize the spinal vertebral segments while protecting and preserve nerve function and not damaging other human body visceral anatomy in order to correct all grades of spondylolisthesis. The proposed solution is to use two implants in the interbody space, allowing greater flexibility to handle high grades of spondylolisthesis that utilize a locking mechanism when the spine has returned to proper alignment to provide the same stability as that of a single implant. Additionally, the reduction system used to realign the spine is designed to minimize the physical strain of the surgeon while realigning the spine, which could have high resistive forces in high grades of spondylolisthesis.  This spinal reduction system is able to treat any grade of spondylolisthesis without supplemental fixation. This is used to treat patients with the spondylolisthesis deformity that causes extreme back or leg pain, and who have found no improvement with more conservative treatment options.
  • Titanium Clip Metal Detector to Aid Breast Surgery
    This titanium metal detector localizes titanium biopsy clips placed at the site of breast tissue biopsies. The device is a handheld metal detector that can be inserted into a surgical incision to help locate small titanium markers without an invasive procedure to insert a localizing wire or radioactive seed. The device uses a two-step detection system which is initiated by running the scanning wand across the patient’s breast as a means of rapidly guiding clinicians to the marker’s general location. Once an approximate location is determined, the probing wand is used to identify the marker’s precise location. An incision is made and the probing wand guides the surgeon’s path to the marker through continuous feedback. The system relates proximity information to clinicians both through auditory feedback mechanisms and a digital display on the base.
  • Cooperative Therapeutic Effect of Immune Checkpoint Blockade & Anti-sMIC
    The invention is a new immune-based therapy modality to treat MIC+ malignancies by the combination of a sMIC neutralizing antibody and an immune checkpoint agonist. This invention presents that a combination of sMIC antibody and anti-CTLA4 or anti-PD1/PD-L1 has superior therapeutic effect over monotherapy of individual reagents. This is a new therapeutic modality to improve the clinic response to anti-CTLA4 or anti-PD1/PD-L1 therapy.  
  • Sachs Wins MUSC FRD's 2017 Innovation Award
    Barton Sachs, M.D., professor of orthopaedics, is the winner of the 2017 Admiral Albert J. Baccioco Innovator of the Year Award, the highest honor awarded by the Medical University of South Carolina’s Foundation for Research Development (FRD). The award recognizes MUSC researchers and clinicians who are working to promote commercialization of university intellectual property through new inventions, patents applied for, technologies licensed, and new startups formed.
    “I appreciate this recognition,” Sachs said. “The annual award is a representation of how the combination of energy, institutional support, team commitment, and social culture can advance innovation and entrepreneurship. I extend my gratitude to FRD and MUSC for the promotion of new ideas and avant-guard solutions to current problems.”

  • Freedom from Cancer Startup Challenge
    Join FRD for an Overview and Networking Session on Monday, September 18 in the Drug Discovery Lobby from 4pm to 7pm.
    What is the Freedom from Cancer Startup Challenge?
    • A startup challenge to launch new startups around cancer inventions
    • An accelerator that provides world class entrepreneurial training
    • Presented by The Center for Advancing Innovation in partnership with the Laura and John Arnold Foundation and MedImmune/AstraZeneca
    RSVP to MUSC FRD Contact: Scott Davis, 843-876-1930, or
  • Hankins joins MUSC Foundation for Research Development
    Brings much experience to director of licensing position
    Mark Hankins has joined MUSC Foundation for Research Development (FRD) as its director of licensing.  In this role, he will assist MUSC faculty in commercializing their inventions and protecting their intellectual property (IP).  Hankins will also market MUSC technologies to prospective licensees, and negotiate licenses or other IP agreements to facilitate the commercialization of MUSC inventions.
    “The MUSC community is looking forward to Mark’s contribution,” said Michael Rusnak, FRD executive director. “His broad experience in both industry and academia will definitely be an asset to our organization and we are thrilled to have him on board.”
  • MUSC Foundation for Research Development Announces Two New Board Members

    Charleston, S.C. (May 25, 2017) – MUSC Foundation for Research Development (FRD) has announced the appointment of two new members to its board of directors, as well as the full slate of directors for 2017-2018.

    Joining the board are William (Bill) Himmelsbach, MPH, FACHE and Julia (Julie) Barnes-Weise, JD, CLP. "Julie and Bill are highly accomplished health care executives with relevant experience and accomplishments to guide FRD as we continue to bring forward technologies in support of the MUSC mission to help patients,” said Arlene Morris, newly-elected chair of the FRD board.  “We look forward to their insights and contributions in support of the FRD mission, and welcome Bill and Julie to the board.”

  • Medical Innovation Interest Group
    Dr. Nancy DeMore, 4 medical students (Ryan Gedney, Matt Hapstack, Alex Cocca, & Elliot Calvert), and MUSC FRD have worked together to create a medical innovation interest group intended to educate medical students on various aspects of inventing new ideas and being physician entrepreneurs. The group will officially get under way in August, 2017. The group will gather monthly, and the students will hear talks on topics ranging from how to write a business plan, how to take a medical device to market, intellectual property, and testimonials from physician entrepreneurs.
    If you are interested in learning more about how you can contribute, please email Chelsea Ex-Lubeskie.
    If you are a medical student and would like to get involved, please email Ryan Gedney, President.
View All TechnologiesFollow Us on Facebook
Follow Us on TwitterFollow Us on LinkedIn!
Harborview Office Tower, 19 Hagood Avenue, Suite 909, Charleston, SC 29403    Ph. 843.876.1900  Fx. 843.876.1905
© 2015 MUSC Foundation for Research Development